

Nandita Khera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2671095/publications.pdf>

Version: 2024-02-01

107
papers

2,392
citations

201674

27
h-index

223800

46
g-index

110
all docs

110
docs citations

110
times ranked

3451
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility of a Digital Storytelling Intervention for Hematopoietic Cell Transplant Patients. <i>Journal of Cancer Education</i> , 2022, 37, 1275-1285.	1.3	4
2	Awareness of myeloma care and the global impact of treatment: An international internet-based prospective study. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 425-433.	0.9	0
3	A hybrid method of healthcare delivery research and human-centered design to develop technology-enabled support for caregivers of hematopoietic stem cell transplant recipients. <i>Supportive Care in Cancer</i> , 2022, 30, 227-235.	2.2	2
4	A mindfulness-based stress management program for caregivers of allogeneic hematopoietic stem cell transplant (HCT) patients: Protocol for a randomized controlled trial. <i>PLoS ONE</i> , 2022, 17, e0266316.	2.5	2
5	Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 419-425.	1.2	2
6	Economic Cost and Sustainability of Oral Therapies in Precision Oncology. <i>JCO Oncology Practice</i> , 2022, 18, e1247-e1254.	2.9	6
7	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <i>Cancer</i> , 2021, 127, 609-618.	4.1	12
8	Does early chimerism testing predict outcomes after allogeneic hematopoietic stem cell transplantation?. <i>Leukemia and Lymphoma</i> , 2021, 62, 252-254.	1.3	5
9	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 556-568.	1.4	34
10	Financial Toxicity in Cancer and Cardiovascular Disease. <i>JACC: CardioOncology</i> , 2021, 3, 247-249.	4.0	6
11	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 679.e1-679.e8.	1.2	10
12	Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation. <i>Cancer</i> , 2021, 127, 4339-4347.	4.1	4
13	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13
14	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 156.	6.2	4
15	How to Sequence Therapies in Mycosis Fungoides. <i>Current Treatment Options in Oncology</i> , 2021, 22, 101.	3.0	3
16	End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Palliative Medicine</i> , 2021, . .	1.1	3
17	Trends in Use and Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Racial/Ethnic Minorities. <i>Blood</i> , 2021, 138, 427-427.	1.4	10
18	The Sustainability of Price Dynamics in Precision Hematology. <i>Blood</i> , 2021, 138, 114-114.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4044-4044.	1.4	0
20	Higher Skeletal Muscle Index Is Associated with Improved Overall Survival in Older Patients with Sarcopenia Undergoing Allogeneic Stem Cell Transplant. <i>Blood</i> , 2021, 138, 3960-3960.	1.4	0
21	Financial Hardship Amongst Patients with Hematologic Malignancies: Using the EMR to Streamline and Prioritize Patient-Centered Care. <i>Blood</i> , 2021, 138, 661-661.	1.4	1
22	Psychosocial and financial issues after hematopoietic cell transplantation. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 570-577.	2.5	5
23	Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. <i>Bone Marrow Transplantation</i> , 2020, 55, 698-707.	2.4	4
24	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.	2.0	13
25	Primary Care Physician Perspectives on Caring for Adult Survivors of Hematologic Malignancies and Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 70-77.	0.4	10
26	Low-Cost Virtual Reality Headsets Reduce Perceived Pain in Healthy Adults: A Multicenter Randomized Crossover Trial. <i>Games for Health Journal</i> , 2020, 9, 129-136.	2.0	12
27	Developing an Educational Intervention to Address Financial Hardship in Cancer Patients. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 424-433.	2.4	15
28	A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e305-e308.	2.0	6
29	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
30	Navigating Ethical Practices in the Era of High Cost Hematology. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 401-407.	2.3	0
31	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
32	The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1747-1756.	2.0	7
33	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Blood Cancer Journal</i> , 2020, 10, 36.	6.2	14
34	Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2020, 61, 1996-2002.	1.3	9
35	Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2019, 54, 204-211.	2.4	41
36	Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 110-117.	1.3	10

#	ARTICLE	IF	CITATIONS
37	Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2086-2090.	2.0	42
38	Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis. <i>BMJ Supportive and Palliative Care</i> , 2019, 9, bmjspcare-2018-001742.	1.6	23
39	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
40	Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?. <i>Leukemia and Lymphoma</i> , 2019, 60, 2034-2041.	1.3	0
41	Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 599-605.	2.0	20
42	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
43	Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 125-134.	2.3	18
44	Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 909-913.	2.0	39
45	Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. <i>Cancer</i> , 2018, 124, 1710-1721.	4.1	40
46	Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1906-1913.	2.0	21
47	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1928-1935.	2.0	2
48	Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 393-399.	2.0	24
49	Financial Hardship after Hematopoietic Cell Transplantation: Lack of Impact on Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 345-347.	2.5	6
50	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018, 74, 130-136.	0.8	47
51	Translation of Clinical Research into Practice: An Impact Assessment of the Results from the Blood and Marrow Transplant Clinical Trials Network Protocol 0201 on Unrelated Graft Source Utilization. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2204-2210.	2.0	11
52	Lost to Follow-up Rates Are Higher in Pediatric Than Adult Survivors, but Not By Transplant Type: A Report from the Center for International Blood and Marrow Transplant Research. <i>Blood</i> , 2018, 132, 2260-2260.	1.4	3
53	The Impact of Marital Status on Hematopoietic Stem Cell Transplant (HCT) Recipient Outcomes: A Surrogate for Consistent Caregiver. a CIBMTR Registry Study. <i>Blood</i> , 2018, 132, 4788-4788.	1.4	1
54	Does Early T Cell Chimerism Predict Outcomes after Allogeneic Hematopoietic Cell Transplantation ?. <i>Blood</i> , 2018, 132, 3360-3360.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Histopathologic Acute Lung Injury after Allogeneic Hematopoietic Cell Transplantation: Clinical Findings, Radiologic Features, Treatments and Outcomes. <i>Blood</i> , 2018, 132, 2113-2113.	1.4	0
56	Area-Based Socioeconomic Status and Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Outcomes: A CIBMTR Analysis. <i>Blood</i> , 2018, 132, 714-714.	1.4	0
57	Prospective Outcomes of Second Line Therapy in Acute Gvhd: Six Month Freedom from Treatment Failure and Day 28 Response in a Multicentre Study. <i>Blood</i> , 2018, 132, 3408-3408.	1.4	0
58	Clinical Outcomes of Matched Unrelated Allogeneic Stem Cell Transplant Patients: Low Dose ATG Vs. No ATG. <i>Blood</i> , 2018, 132, 5715-5715.	1.4	0
59	Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 782-789.	2.0	7
60	Challenges around Access to and Cost of Life-Saving Medications after Allogeneic Hematopoietic Cell Transplantation for Medicare Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1387-1392.	2.0	9
61	Measuring the impact of ambulatory red blood cell transfusion on home functional status: study protocol for a pilot randomized controlled trial. <i>Trials</i> , 2017, 18, 153.	1.6	5
62	Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. <i>Haematologica</i> , 2017, 102, 1823-1832.	3.5	43
63	Setting the stage for universal financial distress screening in routine cancer care. <i>Cancer</i> , 2017, 123, 4092-4096.	4.1	46
64	Conjunctival subepithelial fibrosis and meibomian gland atrophy in ocular graft-versus-host disease. <i>Ocular Surface</i> , 2017, 15, 784-788.	4.4	30
65	Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a <sc>SEER</sc> Medicare analysis. <i>Cancer Medicine</i> , 2017, 6, 2876-2885.	2.8	63
66	Patient-centered care coordination in hematopoietic cell transplantation. <i>Blood Advances</i> , 2017, 1, 1617-1627.	5.2	28
67	Financial Burden and Patient-Reported Outcomes after Hematopoietic Cell Transplantation: Impact of Pre-Treatment Awareness of Transplant-Associated Costs. <i>Blood</i> , 2017, 130, 684-684.	1.4	1
68	Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1319-1323.	2.0	27
69	Oral Chemotherapy in Patients with Hematological Malignancies Care Process, Pharmacoeconomic and Policy Implications. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 288-294.	2.3	11
70	Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2092-2099.	2.0	6
71	Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1504-1510.	2.0	63
72	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 449-455.	2.0	113

#	ARTICLE	IF	CITATIONS
73	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 932-940.	2.0	43
74	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2016, 22, 319-327.	7.0	68
75	Racial Disparity in Drug Utilization Among Multiple Myeloma Patients: A SEER Medicare Analysis. <i>Blood</i> , 2016, 128, 3542-3542.	1.4	1
76	Trends in Disease Presentation, Management, Cost of Care and Outcomes: A Comprehensive Look at Racial Disparities in Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 3544-3544.	1.4	3
77	Differences in Cancer Education Between Patients with Hematologic Malignancies and Solid Tumor Malignancies: Lessons from a Large Multi-Disease Patient Education Symposium. <i>Blood</i> , 2016, 128, 4798-4798.	1.4	4
78	Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A CIBMTR Analysis. <i>Blood</i> , 2016, 128, 842-842.	1.4	0
79	Role of Donor Source on Clinical Outcomes and Inpatient Resource Utilization for Hematopoietic Cell Transplantation in Children with Acute Leukemia. <i>Blood</i> , 2016, 128, 3575-3575.	1.4	0
80	Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis. <i>Blood</i> , 2016, 128, 4653-4653.	1.4	0
81	Beyond Biology: Impact of Center- and Country-specific Economic Factors on Outcomes After Hematopoietic Cell Transplantation. <i>EBioMedicine</i> , 2015, 2, 1869-1870.	6.1	4
82	Reply to J.A. de Souza et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1415-1415.	1.6	0
83	Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1815-1822.	2.0	13
84	Lost in Transition: The Essential Need for Long-Term Follow-Up Clinic for Blood and Marrow Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 225-232.	2.0	85
85	Impact of race and ethnicity on outcomes and health care utilization after allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2015, 56, 987-992.	1.3	14
86	From evidence to clinical practice in blood and marrow transplantation. <i>Blood Reviews</i> , 2015, 29, 351-357.	5.7	6
87	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
88	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 151-158.	2.0	49
89	Reporting and Grading Financial Toxicity. <i>Journal of Clinical Oncology</i> , 2014, 32, 3337-3338.	1.6	73
90	Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1341-1348.	2.0	52

#	ARTICLE	IF	CITATIONS
91	Costs of Allogeneic Hematopoietic Cell Transplantation Using Reduced Intensity Conditioning Regimens. <i>Oncologist</i> , 2014, 19, 639-644.	3.7	36
92	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1777-1784.	2.0	50
93	Financial Burden in Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1375-1381.	2.0	112
94	Lack of association between geographic factors and survival in hematopoietic cell transplantation.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17676-e17676.	1.6	0
95	Patient and provider perspective on financial burden after an allogeneic hematopoietic cell transplantation.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17539-e17539.	1.6	0
96	Costs of Second Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation</i> , 2013, 96, 108-115.	1.0	7
97	Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7034-7034.	1.6	0
98	Do Older Patients With Moderate-Severe Chronic Graft-Versus-Host Disease Differ From Younger Patients?. <i>Blood</i> , 2013, 122, 725-725.	1.4	0
99	Impact Of Vitamin D Level Pre and Post Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2013, 122, 4616-4616.	1.4	2
100	Reduced Toxicity Conditioning With Fludarabine, BCNU, Melphalan and Anti-Thymocyte Globulin Followed By Allogeneic Stem Cell Transplant For Patients With Primary and Post ET/PV Myelofibrosis: Single Center Experience At Mayo Clinic Arizona. <i>Blood</i> , 2013, 122, 2835-2835.	1.4	0
101	Nonmalignant Late Effects and Compromised Functional Status in Survivors of Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 71-77.	1.6	104
102	Economics of hematopoietic cell transplantation. <i>Blood</i> , 2012, 120, 1545-1551.	1.4	145
103	Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US). <i>Blood</i> , 2012, 120, 602-602.	1.4	1
104	Gastrointestinal and Hepatic Involvement in Chronic Gvhd: An Analysis From the Chronic Gvhd Consortium. <i>Blood</i> , 2012, 120, 1940-1940.	1.4	0
105	Impact of Vitamin D Level After Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2012, 120, 1954-1954.	1.4	1
106	Allogenic Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.. <i>Blood</i> , 2012, 120, 2850-2850.	1.4	0
107	Patterns of Acute and Chronic Graft-Versus-Host Disease Following ATG-Based Conditioning for Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 4479-4479.	1.4	0